SHANGHAI, China I June 25, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes ...

ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, PA, USA I June 25, 2025 I ​ Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, ...

Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 ...

FOSTER CITY, CA & WATERTOWN, MA, USA I June 25, 2025 I Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced ...

CAMBRIDGE, MA, USA I June 25, 2025 I Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 ...

NORWOOD, MA, USA I June 25, 2025 I Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on ...

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...

I Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, ...

COPENHAGEN, Denmark I June 26, 2025 I Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support ...

HANGZHOU, China and LONDON, UK I June 24, 2025 I MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, today announced ...